Mandla S G, Byers D M, Ridgway N D, Cook H W
Atlantic Research Centre, Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
Lipids. 1996 Jul;31(7):747-55. doi: 10.1007/BF02522891.
Peroxisomal proliferators and retinoids have been reported to interact to regulate lipid metabolism, particularly beta-oxidation of fatty acids. Based on postulated interactions of these agents at the levels of receptors and response elements, we examined whether interactions exist between the peroxisomal proliferator, clofibrate (CLF), and retinoic acid (RA) in modulation of phospholipid turnover in cultured human skin fibroblasts. Treatment of cultured cells with either 25 microM CLF or 1 microM RA alone decreased [14C]ethanolamine incorporation into ethanolamine phosphoglycerides (EPG) by 20-30%, and simultaneous exposure to both agents resulted in additive inhibition. By contrast, [3H]choline incorporation into phospholipid was stimulated 5-30% by incubation with either agent; when CLF and RA were administered together, the stimulatory effects were additive. Different types of pulse-chase studies examining effects on uptake, biosynthesis, and degradation of labelled phospholipids indicated stimulation of EPG degradation and inhibition of phosphatidylcholine degradation by CLF; no effect on catabolism of either phospholipid was observed with RA. Combinations of modifiers of protein kinase activity [4 beta-12-O-tetradecanoylphorbol-13-acetate (beta-TPA), 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride, N-(2'-guanidinoethyl)-5-isoquinolinesulfonamide hydrochloride, bis-indolylmaleimide, staurosporine indicated that beta-TPA-responsive protein kinases were not involved. Accordingly, CLF and RA regulate biosynthesis and degradation of ethanolamine and choline phosphoglycerides in cultured skin fibroblasts by different mechanisms that do not involve classical protein kinase C (PKC) isoforms, even though turnover of phospholipids generating lipid activators of PKC occurs.
据报道,过氧化物酶体增殖剂和类视黄醇相互作用以调节脂质代谢,尤其是脂肪酸的β-氧化。基于这些物质在受体和反应元件水平上的假定相互作用,我们研究了过氧化物酶体增殖剂氯贝丁酯(CLF)和视黄酸(RA)在调节培养的人皮肤成纤维细胞磷脂周转过程中是否存在相互作用。单独用25μM CLF或1μM RA处理培养的细胞,可使[14C]乙醇胺掺入乙醇胺磷酸甘油酯(EPG)的量减少20 - 30%,同时暴露于两种物质会导致相加性抑制。相比之下,用任何一种物质孵育可使[3H]胆碱掺入磷脂的量增加5 - 30%;当CLF和RA一起给药时,刺激作用是相加的。不同类型的脉冲追踪研究检测对标记磷脂摄取、生物合成和降解的影响,结果表明CLF刺激EPG降解并抑制磷脂酰胆碱降解;RA对两种磷脂的分解代谢均无影响。蛋白激酶活性调节剂[4β - 12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯(β - TPA)、1 - (5 - 异喹啉磺酰基) - 2 - 甲基哌嗪二盐酸盐、N - (2'-胍基乙基) - 5 - 异喹啉磺酰胺盐酸盐、双吲哚马来酰亚胺、星形孢菌素]的组合表明,β - TPA反应性蛋白激酶不参与其中。因此,CLF和RA通过不同机制调节培养的皮肤成纤维细胞中乙醇胺和胆碱磷酸甘油酯的生物合成和降解,这些机制不涉及经典的蛋白激酶C(PKC)同工型,尽管会发生产生PKC脂质激活剂的磷脂周转。